Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gefitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03292133
What this trial is testing

EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 11
Testing effectiveness (Phase 2)Study completedNCT00570401
What this trial is testing

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 22
Large-scale testing (Phase 3)UnknownNCT04874844
What this trial is testing

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Who this might be right for
NSCLC
Beijing Dongfang Biotech Co., Ltd. 420
Testing effectiveness (Phase 2)UnknownNCT03374280
What this trial is testing

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Guangzhou Medical University 178
Post-approval studies (Phase 4)Study completedNCT01203917
What this trial is testing

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
AstraZeneca 1,060
Large-scale testing (Phase 3)UnknownNCT00006049
What this trial is testing

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
AstraZeneca
Post-approval studies (Phase 4)Study completedNCT00608868
What this trial is testing

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Who this might be right for
Non Small Cell Lung Carcinoma
AstraZeneca 156
Not applicableStudy completedNCT00068497
What this trial is testing

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Who this might be right for
Anaplastic Thyroid CancerInsular Thyroid CancerMetastatic Parathyroid Cancer+83 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)UnknownNCT01732276
What this trial is testing

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangmen Central Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00025207
What this trial is testing

Gefitinib in Treating Patients With Malignant Mesothelioma

Who this might be right for
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant Mesothelioma+1 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT02179671
What this trial is testing

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
AstraZeneca 32
Testing effectiveness (Phase 2)UnknownNCT03457337
What this trial is testing

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Who this might be right for
Advanced NSCLC With EGFR Mutation
Henan Cancer Hospital 200
Testing effectiveness (Phase 2)Study completedNCT00012337
What this trial is testing

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT01288430
What this trial is testing

DS-2248 in Participants With Advanced Solid Tumors

Who this might be right for
Solid TumorsNon-small Cell Lung Carcinoma
Daiichi Sankyo 60
Testing effectiveness (Phase 2)Study completedNCT00052754
What this trial is testing

Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Who this might be right for
Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC 48
Testing effectiveness (Phase 2)Study completedNCT00632723
What this trial is testing

IRESSA™ (Gefitinib) in Breast Cancer Patients

Who this might be right for
Breast Cancer
AstraZeneca 54
Testing effectiveness (Phase 2)UnknownNCT04425187
What this trial is testing

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Who this might be right for
PFS
Fudan University 120
Testing effectiveness (Phase 2)Ended earlyNCT00052585
What this trial is testing

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer

Who this might be right for
Adenocarcinoma of the ColonAdenocarcinoma of the RectumMucinous Adenocarcinoma of the Colon+7 more
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00181688
What this trial is testing

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CarcinomaTubal Carcinoma
Massachusetts General Hospital 35
Testing effectiveness (Phase 2)Study completedNCT00265070
What this trial is testing

Trial of Iressa in Prostate Cancer Patients

Who this might be right for
Prostate Cancer
AstraZeneca 80
Next Page